NCT01308021 - Clinical Efficacy and Safety of gpASIT+TM to Treat Seasonal Allergic Rhinoconjunctivitis | Biotech Hunter

Enrollment

202

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

October 31, 2011

Study Completion Date

December 31, 2011

Conditions

Grass Pollen AllergyHay Fever

Interventions

BIOLOGICAL

gpASIT+TM

entero-coated capsules containing 400µg of gpASIT+TM, daily , 28 days

BIOLOGICAL

gpASIT+TM

entero-coated capsules containing 800 µg of gpASIT+TM, daily, 28 days

BIOLOGICAL

Placebo

Placebo entero-coated capsules

Trial Locations (19)

1040

Clinique du Parc Léopold, Brussels

1090

UZ Brussel, Brussels

1200

UCL Saint Luc, Brussels

1210

CH Luxembourg, Luxembourg

2650

UZ Antwerpen, Edegem

3000

UZ Leuven, Leuven

4000

CHR Citadelle, Liège

CHU Sart-Tilman, Liège

5530

UCL Mont Godinne, Yvoir

7000

CHU Ambroise Paré, Mons

7300

CHR Saint Joseph Warquignies, Boussu

8310

AZ Sint Lucas, Bruges

9000

UZ Gent, Ghent

44000

Private practice, Nantes

44400

Private practice, Nantes

51100

CHU Reims, Reims

59020

Hôpital Saint Vincent de Paul, Lille

59037

CHRU Lille, Lille

67091

CHRU Strasbourg, Strasbourg